A number of Chinese pharma companies are showcasing the latest clinical results for their oncology R&D arsenals in oral abstract sessions at the American Society of Clinical Oncology (ASCO) meeting, being held in Chicago over 2-6 June.
Of all presentations released on 25 May, the most eye-catching abstracts focused on potential therapies for lung cancer, one of the most prevalent types of malignancy in China.